Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Paratek Pharma Inc (NQ: PRTK )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Paratek Pharma Inc

< Previous 1 2 3 4 Next >
Earnings Outlook For Paratek Pharmaceuticals
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Paratek Pharmaceuticals: Q4 Earnings Insights
Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement... 
Via Benzinga
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
Paratek Pharmaceuticals's Earnings: A Preview
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
Zai Lab's Nuzyra Approved In China For Bacterial Infections
The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral... 
Via Benzinga
Recap: Paratek Pharmaceuticals Q3 Earnings
Paratek Pharmaceuticals (NASDAQ:PRTK) reported its Q3 earnings results on Monday, November 8, 2021 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Paratek Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA 
Via Benzinga
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
Paratek Secures BARDA Funding To Develop Nuzyra Antibiotic For Pulmonary Anthrax
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an option under Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) Project... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK... 
Via Benzinga
48 Biggest Movers From Friday
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, Inc. (NYSE: CWAN) surged 40.9% to settle at $25.37... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume for Molecular Templates's stock is 937.9K as... 
Via Benzinga
34 Stocks Moving In Friday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares jumped 76.2% to $6.08. Unique Fabricating, Inc. (NASDAQ: UFAB) jumped 37.7% to $3.47. Form 4 filings from late Thursday... 
Via Benzinga
How Good Are Paratek Pharmaceuticals's Earnings? | Return On Capital Employed
According to Benzinga Pro, during Q2, Paratek Pharmaceuticals (NASDAQ:PRTK) earned $14.09 million, a 199.07% increase from the preceding quarter. Paratek Pharmaceuticals also... 
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Paratek's Antibiotic Gets FDA Orphan Drug Tag For Lung Infection
The FDA has granted Orphan Drug Designation to Paratek Pharmaceuticals Inc's (NASDAQ: PRTK), Nuzyra (omadacycline) for infections caused by Nontuberculous... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Protagenic Therapeutics (NASDAQ:PTIX... 
Via Benzinga
Paratek Pharmaceuticals (PRTK) Q2 2021 Earnings Call Transcript
PRTK earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Paratek Pharmaceuticals: Q2 Earnings Insights
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74%... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.